Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation: Sub-analysis in Japanese population in RE-LY trial

Circulation Journal

Volumn 75, Issue 4, 2011, Pages 800-805

  Hori, Masatsugu ^a   Connolly, Stuart J ^b   Ezekowitz, Michael D ^c   Reilly, Paul A ^d   Yusuf, Salim ^b   Wallentin, Lars ^e  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

Author keywords

Atrial fibrillation; Bleeding; Dabigatran; Ischemic hemorrhage stroke; Japanese cohort

Indexed keywords

DABIGATRAN; WARFARIN;

AGED; ARTHRALGIA; ARTICLE; BACKACHE; BLEEDING; BRAIN HEMORRHAGE; CATARACT; CEREBROVASCULAR ACCIDENT; CONSTIPATION; CONTROLLED STUDY; CONTUSION; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ECZEMA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIODONTITIS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RASH; REFLUX ESOPHAGITIS; RHINOPHARYNGITIS; RISK REDUCTION; THORAX PAIN; VOMITING;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HEMORRHAGE; HUMANS; JAPAN; MALE; STROKE; WARFARIN;

EID: 79953656178     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0191     Document Type: Article

References (14)

1. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation). Circulation 2001; 104: 2118-2150.
2. Takahashi A, Kuwahara T, Takahashi Y. Complications in the catheter ablation of atrial fibrillation: Incidence and management. Circ J 2009; 73: 221-226.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
4. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis. Thromb Res 2006; 118: 321-333.
5. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1877.
8. Ezekowitz MD, Connolly SJ, Parekh A, Reilly PA, Varrone J, Wang S, et al. Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157: 805-810.
9. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001; 40: 1183-1188.
10. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation an individual patient meta-analysis. JAMA 2002; 288: 2441-2448.
11. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007; 3: CD006186.
12. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of Intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309-315.
13. Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, Barkun A, Thomson A, Smyth S, et al. Randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: The CADET-HN Study. Am J Gastroenterol 2005; 100: 1477-1488.
14. Diener HC; Executive Steering Committee of the SPORTIFF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation: Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006; 21: 279-293.